These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 15167306)

  • 1. Effect of raloxifene on quality of life: a prospective study using the Utian Quality of Life (UQOL) Scale.
    Utian WH; Janata JW; Barbier S; Rosen AS; Mayer MH; Taylor MB
    Menopause; 2004; 11(3):275-80. PubMed ID: 15167306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, double-blind trial comparing raloxifene HCl and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life.
    Voss S; Quail D; Dawson A; Bäckström T; Aguas F; Erenus M; The HS; Bonnar J; De Geyter C; Hunter M; Nickelsen T;
    BJOG; 2002 Aug; 109(8):874-85. PubMed ID: 12197366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
    Land SR; Wickerham DL; Costantino JP; Ritter MW; Vogel VG; Lee M; Pajon ER; Wade JL; Dakhil S; Lockhart JB; Wolmark N; Ganz PA
    JAMA; 2006 Jun; 295(23):2742-51. PubMed ID: 16754728
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Raloxifene and estrogen effects on quality of life in healthy postmenopausal women: a placebo-controlled randomized trial.
    Strickler R; Stovall DW; Merritt D; Shen W; Wong M; Silfen SL
    Obstet Gynecol; 2000 Sep; 96(3):359-65. PubMed ID: 10960626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mood effect of raloxifene in postmenopausal women.
    Jarkova NB; Martenyi F; Masanauskaite D; Walls EL; Smetnik VP; Pavo I
    Maturitas; 2002 May; 42(1):71-5. PubMed ID: 12020982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Raloxifene improves verbal memory in late postmenopausal women: a randomized, double-blind, placebo-controlled trial.
    Jacobsen DE; Samson MM; Emmelot-Vonk MH; Verhaar HJ
    Menopause; 2010 Mar; 17(2):309-14. PubMed ID: 19918203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.
    Cohen FJ; Lu Y
    Maturitas; 2000 Jan; 34(1):65-73. PubMed ID: 10687884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium-a pilot study.
    Davis SR; O'Neill SM; Eden J; Baber R; Ekangaki A; Stocks JM; Thiebaud D
    Menopause; 2004; 11(2):167-75. PubMed ID: 15021446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.
    Johnston CC; Bjarnason NH; Cohen FJ; Shah A; Lindsay R; Mitlak BH; Huster W; Draper MW; Harper KD; Heath H; Gennari C; Christiansen C; Arnaud CD; Delmas PD
    Arch Intern Med; 2000 Dec 11-25; 160(22):3444-50. PubMed ID: 11112238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.
    Meunier PJ; Vignot E; Garnero P; Confavreux E; Paris E; Liu-Leage S; Sarkar S; Liu T; Wong M; Draper MW
    Osteoporos Int; 1999; 10(4):330-6. PubMed ID: 10692984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial.
    Barrett-Connor E; Grady D; Sashegyi A; Anderson PW; Cox DA; Hoszowski K; Rautaharju P; Harper KD;
    JAMA; 2002 Feb; 287(7):847-57. PubMed ID: 11851576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes.
    Barrett-Connor E; Ensrud KE; Harper K; Mason TM; Sashegyi A; Krueger KA; Anderson PW
    Clin Ther; 2003 Mar; 25(3):919-30. PubMed ID: 12852708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial.
    Reginster JY; Felsenberg D; Pavo I; Stepan J; Payer J; Resch H; Glüer CC; Mühlenbacher D; Quail D; Schmitt H; Nickelsen T
    Osteoporos Int; 2003 Sep; 14(9):741-9. PubMed ID: 12827224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raloxifene: a review of its use in postmenopausal osteoporosis.
    Clemett D; Spencer CM
    Drugs; 2000 Aug; 60(2):379-411. PubMed ID: 10983739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of raloxifene on endothelium-dependent dilation, lipoproteins, and markers of vascular function in postmenopausal women with coronary artery disease.
    Griffiths KA; Sader MA; Skilton MR; Harmer JA; Celermajer DS
    J Am Coll Cardiol; 2003 Aug; 42(4):698-704. PubMed ID: 12932604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translation and validation of the Utian Quality of Life Scale in Serbian peri- and postmenopausal women.
    Dotlic J; Gazibara T; Rancic B; Radovanovic S; Milosevic B; Kurtagic I; Nurkovic S; Kovacevic N; Utian W
    Menopause; 2015 Sep; 22(9):984-92. PubMed ID: 25628058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.
    Cauley JA; Norton L; Lippman ME; Eckert S; Krueger KA; Purdie DW; Farrerons J; Karasik A; Mellstrom D; Ng KW; Stepan JJ; Powles TJ; Morrow M; Costa A; Silfen SL; Walls EL; Schmitt H; Muchmore DB; Jordan VC; Ste-Marie LG
    Breast Cancer Res Treat; 2001 Jan; 65(2):125-34. PubMed ID: 11261828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Raloxifene Plus Antipsychotics Versus Placebo Plus Antipsychotics in Severely Ill Decompensated Postmenopausal Women With Schizophrenia or Schizoaffective Disorder: A Randomized Controlled Trial.
    Weiser M; Levi L; Burshtein S; Hagin M; Matei VP; Podea D; Micluția I; Tiugan A; Păcală B; Grecu IG; Noy A; Zamora D; Davis JM
    J Clin Psychiatry; 2017 Jul; 78(7):e758-e765. PubMed ID: 28541645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Placebo-Controlled Study of Raloxifene Added to Risperidone in Men with Chronic Schizophrenia.
    Khodaie-Ardakani MR; Khosravi M; Zarinfard R; Nejati S; Mohsenian A; Tabrizi M; Akhondzadeh S
    Acta Med Iran; 2015; 53(6):337-45. PubMed ID: 26069170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum estradiol level and risk of breast cancer during treatment with raloxifene.
    Cummings SR; Duong T; Kenyon E; Cauley JA; Whitehead M; Krueger KA;
    JAMA; 2002 Jan; 287(2):216-20. PubMed ID: 11779264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.